RBC Capital analyst Ben Hendrix raised the firm’s price target on Chemed (CHE) to $674 from $667 and keeps an Outperform rating on the shares after its Q1 earnings beat. The firm remains positive on the stock following a “solid” Q1 report and given an improved outlook for Roto-Rooter, the analyst tells investors in a research note. Concerns over potential Medicare cap limitations are overblown with the company proactively managing with shorter-stay hospital admissions in select markets, RBC adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHE:
- Chemed’s Earnings Call: Mixed Sentiment with Growth and Challenges
- Chemed Corporation Reports Strong Q1 2025 Results
- Chemed’s Strong Q1 Performance and Growth Potential Justify Buy Rating
- Chemed reports Q1 adjusted EPS $5.63, consensus $5.55
- CHE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue